Skip to main content

Advertisement

SpringerLink
Log in

Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

We prospectively evaluated long-term (12 months) effects of telmisartan on blood pressure (BP), circulating renin-anigiotensin-aldosterone levels, and lipids in hypertensive patients. There were 13 men and 11 women, 59 ± 8.7 years of age (mean ± SEM), with untreated essential hypertension. The 20-60 mg doses of telmisartan were administered once daily in the morning until BP130/85 was obtained. Blood pressure and plasma renin activity, plasma angiotensin (Ang) I and Ang II, serum angiotensin-converting enzyme (ACE) activity, plasma aldosterone concentration, plasma human atrial natriuretic peptide (hANP) concentration, and serum lipids were obtained 6 and 12 months after starting telmisartan administration. Systolic and diastolic BP were significantly (P < 0.001, P < 0.001) decreased from 162 ± 3.3 and 97.7 ± 2.1 mmHg to 128 ± 3.8 and 79.6 ± 2.0 mmHg after 12 months of treatment, respectively. Plasma Ang I and Ang II were unchanged at 12 months. Plasma renin activity and serum ACE activity were significantly (P < 0.001, P < 0.05) increased and plasma aldosterone concentration was unchanged during the study period. Total cholesterol levels were unchanged, but serum triglycerides levels were significantly decreased at 12 months (P < 0.01). Plasma hANP showed no significant alteration throughout the 12-month period. In hypertensive patients, telmisartan is a beneficial antihypertensive drug that also lowers serum triglycerides.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ogihara T, Higashimori K, Masuo K, Mikami H (1993) Pilot study of a new angiotensin II receptor antagonist, TCV-116: effects of a single oral dose on blood pressure in patients with essential hypertension. Clin Ther 15:684–691

    CAS  PubMed  Google Scholar 

  2. Kang PM, Landau AJ, Eberhardt RT, Frishman WH (1993) Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J 127:1388–1401

    Article  Google Scholar 

  3. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD (1993) Angiotensin II receptors and angiotensin II receptor antagonist. Pharmacol Rev 45:205–251

    CAS  PubMed  Google Scholar 

  4. Matsubara H (1998) Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 83:1182–1191

    CAS  PubMed  Google Scholar 

  5. Carey RM, Wang ZQ, Siragy HM (2000) Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 35:155–163

    CAS  PubMed  Google Scholar 

  6. Tsutsumi Y, Matsubara H, Ohkubo N, Mori Y, Nozawa Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Moriguchi Y, Shibasaki Y, Kamihara H, Inada M, Iwasaka T (1998) Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis and cardiac fibroblasts are the major cell type for its expression. Circ Res 83:1035–1046

    CAS  PubMed  Google Scholar 

  7. Oishi Y, Ozono R, Yano Y, Teranishi Y, Akishita M, Horiuchi M, Oshima T, Kambe M (2003) Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension 41(part 2):814–818

    Article  CAS  PubMed  Google Scholar 

  8. Waeber B, Brunner HR (1996) Angiotensin II antagonists: a new class of antihypertensive agent. Br J Clin Pract 50:265–268

    CAS  PubMed  Google Scholar 

  9. Sharpe M, Jarvis B, Goa KL (2001) Telmisartan: a review of its use in hypertension. Drugs 61:1501–1529

    Article  CAS  PubMed  Google Scholar 

  10. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R (2004) Effects of telmisartan compaired with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 27:457–464

    Article  CAS  PubMed  Google Scholar 

  11. Gavras I, Gavras H (1999) Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin 15:15–24

    Article  CAS  PubMed  Google Scholar 

  12. Grossman E, Peleg E, Carroll J, Shamiss A, Rosenthal T (1994) Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 7:1041–1044

    CAS  PubMed  Google Scholar 

  13. Bauer IH, Reams GP, Wu Z, Lau-Sieckman A (1995) Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. J Hum Hypertens 9:237–243

    CAS  PubMed  Google Scholar 

  14. Ichikawa S, Takayama Y (2001) Long-term effects of olmesartan, an ang II receptor antagonist, on blood pressure and the rennin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res 24:641–646

    Article  CAS  PubMed  Google Scholar 

  15. Fernandes-Santos C, de Souza Mendonca L, Mandarim-de-Lacerda CA (2009) Favorable cardiac and aortic remodeling in ormesartan-treated spontaneously hypertensive rats. Heart Vessels 24: 219–227

    Article  PubMed  Google Scholar 

  16. Umeda M, Ichikawa S, Kanda T, Sumino H, Kobayashi I (2001) Hormone replacement therapy increases plasma level of angiotensin II in postmenopausal hypertensive women. Am J Hypertens 14:206–211

    Article  CAS  PubMed  Google Scholar 

  17. Yamamoto T, Hiromoto J, Kikuchi Y, Oka M, Takatori O (1989) Correlations among blood levels of renin-angiotensin-aldosterone, bradykinin, and catecholamines in healthy subjects. Clin Chim Acta 181:197–200

    Article  CAS  PubMed  Google Scholar 

  18. Kasahara Y, Ashihara Y (1981) Colorimetry of angiotensin-I converting enzyme activity in serum. Clin Chem 27:1922–1925

    CAS  PubMed  Google Scholar 

  19. Galzerano D, Tammaro P, del Viscovo L, Lama D, Galzerano A, Breglio R, Tuccillo B, Paolisso G, Capogrosso P (2005) Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass. A multicenter, randomized, longitudinal study. Am J Hypertens 18:1563–1569

    Article  CAS  PubMed  Google Scholar 

  20. The ONTARGET investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559

    Article  Google Scholar 

  21. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R (2004) Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 27:457–464

    Article  CAS  PubMed  Google Scholar 

  22. Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R for the Valsartan Heart Failure Trial investigators (2003) Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure. Results from the valsartan heart failure trial. Circulation 108:1306–1309

    CAS  Google Scholar 

  23. Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G (1995) Biochemical effects of losartan, a nenpeptide Ang II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 25:37–46

    CAS  PubMed  Google Scholar 

  24. Campbell DJ, Kladis A, Valentijn AJ (1995) Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharm 26:233–240

    CAS  Google Scholar 

  25. Mukawa H, Toki Y, Shimauchi A, Matsui H, Morishima I, Okumura K, Ito T, Hayakawa T (1997) Pressure overload per se rather than cardiac angiotensin converting enzyme activity may be important in the development of rat cardiac hypertrophy. J Hypertens 15:1027–1032

    Article  CAS  PubMed  Google Scholar 

  26. Shibasaki Y, Mori Y, Tsutsumi Y, Masaki H, Sakamoto K, Murasawa S, Maruyama K, Moriguchi Y, Tanaka Y, Iwasaka T, Inada M, Matsubara H (1999) Differential kinetics of circulating Ang IV and II after treatment with Ang II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure. Clin Nephrol 51:83–91

    CAS  PubMed  Google Scholar 

  27. Wagner J, Drab M, Bohlender J, Amann K, Wienen W, Ganten D (1998) Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens 20:205–221

    Article  CAS  PubMed  Google Scholar 

  28. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM (2004) Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43:970–976

    Article  CAS  PubMed  Google Scholar 

  29. Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann Tallant E, Smith RD, Chappell MC (2005) Effects of reninangiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 68:2189–2196

    Article  CAS  PubMed  Google Scholar 

  30. Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM (2006) Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol 291: H2166–H2172

    Article  CAS  PubMed  Google Scholar 

  31. Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, Taniguchi S, Shimamoto K (2006) Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 29:865–874

    Article  CAS  PubMed  Google Scholar 

  32. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM (2005) Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1–7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289:H1013–H1019

    Article  CAS  PubMed  Google Scholar 

  33. Shunkert H, Ingelfinger JR, Hirsch AT, Pinto Y, Remme WJ, Jacob H, Dzau VJ (1993) Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ Res 72:312–318

    Google Scholar 

  34. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, Thone-Reineke C, Unger T, Kintscher U (2005) PPARγ-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46:137–143

    Article  CAS  PubMed  Google Scholar 

  35. Ernsberger P, Koletsky RJ (2007) Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect? Curr Opin Pharmacol 7:140–145

    Article  CAS  PubMed  Google Scholar 

  36. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43:993–1002

    Article  CAS  PubMed  Google Scholar 

  37. Yamamoto T, Shirayama T, Takahashi T, Matsubara H (2009) Altered expression of Na+ transporters at the mRNA level in rat normal and hypertrophic myocardium. Heart Vessels 24:54–62

    Article  PubMed  Google Scholar 

  38. Parker AB, Azevedo ER, Baird MG, Smith SJ, Arnold JM, Humen DP, Moe GW, Parker JO, Butt RW, Parker JD (1999) ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada. Am Heart J 138:843–848

    Article  CAS  PubMed  Google Scholar 

  39. Ogihara T, Shima J (1987) Changes in plasma atrial natriuretic polypeptide concentration during head-out water immersion and saline infusion in normal men. Jpn Heart J 28:41–51

    CAS  PubMed  Google Scholar 

  40. Kojima S, Inoue I, Hirata Y, Saito F, Yoshida K, Abe H, Deguchi F, Kawano Y, Kimura G, Yoshimi H (1987) Effects of changes in dietary sodium intake and saline infusion on plasma atrial natriuretic peptide in hypertensive patients. Clin Exp Hypertens A 9:1243–1258

    Article  CAS  PubMed  Google Scholar 

  41. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293–302

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Kidney Center, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

    Akiko Aoki, Tetsuya Ogawa & Kosaku Nitta

  2. Cardiovascular Hospital of Central Japan, Gunma, Japan

    Hiroyuki Sumino, Hisao Kumakura, Yoshiaki Takayama & Shuichi Ichikawa

  3. Department of Nursing, Faculty of Nursing, Takasaki University of Health and Welfare, Takasaki, Japan

    Hiroyuki Sumino

Authors
  1. Akiko Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsuya Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroyuki Sumino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hisao Kumakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshiaki Takayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shuichi Ichikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kosaku Nitta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kosaku Nitta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aoki, A., Ogawa, T., Sumino, H. et al. Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients. Heart Vessels 25, 195–202 (2010). https://doi.org/10.1007/s00380-009-1186-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-009-1186-6

Key words

Search

Navigation